Search

Your search keyword '"Dworzak, Michael N."' showing total 269 results
Start Over Author "Dworzak, Michael N."
269 results on '"Dworzak, Michael N."'

4. Immunological Diagnosis

Author

Maurer-Granofszky, Margarita, Dworzak, Michael N., Schneider, Dominik, Series Editor, Reinhardt, Dirk, Series Editor, Escherich, Gabriele, editor, and Conter, Valentino, editor

Published
2024
Full Text
View/download PDF

5. Azacitidine (Vidaza®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015)

Author

Rubio-San-Simón, Alba, van Eijkelenburg, Natasha K. A., Hoogendijk, Raoull, Hasle, Henrik, Niemeyer, Charlotte M., Dworzak, Michael N., Zecca, Marco, Lopez-Yurda, Marta, Janssen, Julie M., Huitema, Alwin D. R., van den Heuvel-Eibrink, Marry M., Laille, Eric J., van Tinteren, Harm, and Zwaan, Christian M.

Published
2023
Full Text
View/download PDF

6. Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia

Author

van Weelderen, Romy E., Harrison, Christine J., Klein, Kim, Jiang, Yilin, Abrahamsson, Jonas, Alonzo, Todd, Aplenc, Richard, Arad-Cohen, Nira, Bart-Delabesse, Emmanuelle, Buldini, Barbara, De Moerloose, Barbara, Dworzak, Michael N., Elitzur, Sarah, Fernández Navarro, José M., Gamis, Alan, Gerbing, Robert B., Goemans, Bianca F., de Groot-Kruseman, Hester A., Guest, Erin, Ha, Shau-Yin, Hasle, Henrik, Kelaidi, Charikleia, Lapillonne, Hélène, Leverger, Guy, Locatelli, Franco, Miyamura, Takako, Norén-Nyström, Ulrika, Polychronopoulou, Sophia, Rasche, Mareike, Rubnitz, Jeffrey E., Stary, Jan, Tierens, Anne, Tomizawa, Daisuke, Zwaan, C. Michel, and Kaspers, Gertjan J. L.

Published
2024
Full Text
View/download PDF

7. CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment

Author

Buldini, Barbara, Varotto, Elena, Maurer-Granofszky, Margarita, Gaipa, Giuseppe, Schumich, Angela, Brüggemann, Monika, Mejstrikova, Ester, Cazzaniga, Giovanni, Hrusak, Ondrej, Szczepanowski, Monika, Scarparo, Pamela, Zimmermann, Martin, Strehl, Sabine, Schinnerl, Dagmar, Zaliova, Marketa, Karawajew, Leonid, Bourquin, Jean-Pierre, Feuerstein, Tamar, Cario, Gunnar, Alten, Julia, Möricke, Anja, Biffi, Alessandra, Parasole, Rosanna, Fagioli, Franca, Valsecchi, Maria Grazia, Biondi, Andrea, Locatelli, Franco, Attarbaschi, Andishe, Schrappe, Martin, Conter, Valentino, Basso, Giuseppe, and Dworzak, Michael N.

Published
2024
Full Text
View/download PDF

8. Towards Self-explainable Transformers for Cell Classification in Flow Cytometry Data

Author

Kowarsch, Florian, Weijler, Lisa, Wödlinger, Matthias, Reiter, Michael, Maurer-Granofszky, Margarita, Schumich, Angela, Sajaroff, Elisa O., Groeneveld-Krentz, Stefanie, Rossi, Jorge G., Karawajew, Leonid, Ratei, Richard, Dworzak, Michael N., Goos, Gerhard, Founding Editor, Hartmanis, Juris, Founding Editor, Bertino, Elisa, Editorial Board Member, Gao, Wen, Editorial Board Member, Steffen, Bernhard, Editorial Board Member, Yung, Moti, Editorial Board Member, Reyes, Mauricio, editor, Henriques Abreu, Pedro, editor, and Cardoso, Jaime, editor

Published
2022
Full Text
View/download PDF

10. Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia

Author

Arts-assistenten Radiotherapie, Arts-assistenten Kinderen, PMC Medisch specialisten, Child Health, Speerpunt, van Weelderen, Romy E., Harrison, Christine J., Klein, Kim, Jiang, Yilin, Abrahamsson, Jonas, Alonzo, Todd, Aplenc, Richard, Arad-Cohen, Nira, Bart-Delabesse, Emmanuelle, Buldini, Barbara, De Moerloose, Barbara, Dworzak, Michael N., Elitzur, Sarah, Fernández Navarro, José M., Gamis, Alan, Gerbing, Robert B., Goemans, Bianca F., de Groot-Kruseman, Hester A., Guest, Erin, Ha, Shau Yin, Hasle, Henrik, Kelaidi, Charikleia, Lapillonne, Hélène, Leverger, Guy, Locatelli, Franco, Miyamura, Takako, Norén-Nyström, Ulrika, Polychronopoulou, Sophia, Rasche, Mareike, Rubnitz, Jeffrey E., Stary, Jan, Tierens, Anne, Tomizawa, Daisuke, Zwaan, C. Michel, Kaspers, Gertjan J.L., Arts-assistenten Radiotherapie, Arts-assistenten Kinderen, PMC Medisch specialisten, Child Health, Speerpunt, van Weelderen, Romy E., Harrison, Christine J., Klein, Kim, Jiang, Yilin, Abrahamsson, Jonas, Alonzo, Todd, Aplenc, Richard, Arad-Cohen, Nira, Bart-Delabesse, Emmanuelle, Buldini, Barbara, De Moerloose, Barbara, Dworzak, Michael N., Elitzur, Sarah, Fernández Navarro, José M., Gamis, Alan, Gerbing, Robert B., Goemans, Bianca F., de Groot-Kruseman, Hester A., Guest, Erin, Ha, Shau Yin, Hasle, Henrik, Kelaidi, Charikleia, Lapillonne, Hélène, Leverger, Guy, Locatelli, Franco, Miyamura, Takako, Norén-Nyström, Ulrika, Polychronopoulou, Sophia, Rasche, Mareike, Rubnitz, Jeffrey E., Stary, Jan, Tierens, Anne, Tomizawa, Daisuke, Zwaan, C. Michel, and Kaspers, Gertjan J.L.

Published
2024

11. Selective pressures of platinum compounds shape the evolution of therapy-related myeloid neoplasms

Author

Bertrums, Eline J.M., de Kanter, Jurrian K., Derks, Lucca L.M., Verheul, Mark, Trabut, Laurianne, van Roosmalen, Markus J., Hasle, Henrik, Antoniou, Evangelia, Reinhardt, Dirk, Dworzak, Michael N., Mühlegger, Nora, van den Heuvel-Eibrink, Marry M., Zwaan, C. Michel, Goemans, Bianca F., van Boxtel, Ruben, Bertrums, Eline J.M., de Kanter, Jurrian K., Derks, Lucca L.M., Verheul, Mark, Trabut, Laurianne, van Roosmalen, Markus J., Hasle, Henrik, Antoniou, Evangelia, Reinhardt, Dirk, Dworzak, Michael N., Mühlegger, Nora, van den Heuvel-Eibrink, Marry M., Zwaan, C. Michel, Goemans, Bianca F., and van Boxtel, Ruben

Abstract

Therapy-related myeloid neoplasms (t-MN) arise as a complication of chemo- and/or radiotherapy. Although t-MN can occur both in adult and childhood cancer survivors, the mechanisms driving therapy-related leukemogenesis likely vary across different ages. Chemotherapy is thought to induce driver mutations in children, whereas in adults pre-existing mutant clones are selected by the exposure. However, selective pressures induced by chemotherapy early in life are less well studied. Here, we use single-cell whole genome sequencing and phylogenetic inference to show that the founding cell of t-MN in children starts expanding after cessation of platinum exposure. In patients with Li-Fraumeni syndrome, characterized by a germline TP53 mutation, we find that the t-MN already expands during treatment, suggesting that platinum-induced growth inhibition is TP53-dependent. Our results demonstrate that germline aberrations can interact with treatment exposures in inducing t-MN, which is important for the development of more targeted, patient-specific treatment regimens and follow-up.

Published
2024

12. FCM marker importance for MRD assessment in T‐Cell Acute Lymphoblastic Leukemia: An AIEOP‐BFM‐ALL‐FLOW Study Group Report

Author

Kowarsch, Florian, primary, Maurer‐Granofszky, Margarita, additional, Weijler, Lisa, additional, Wödlinger, Matthias, additional, Reiter, Michael, additional, Schumich, Angela, additional, Feuerstein, Tamar, additional, Sala, Simona, additional, Nováková, Michaela, additional, Faggin, Giovanni, additional, Gaipa, Giuseppe, additional, Hrusak, Ondrej, additional, Buldini, Barbara, additional, and Dworzak, Michael N., additional

Published
2023
Full Text
View/download PDF

13. Measurable residual disease and fusion partner independently predict survival and relapse risk in childhood KMT2A-rearranged acute myeloid leukemia : a study by the international Berlin-Frankfurt-Münster study group

Author

van Weelderen, Romy E., Klein, Kim, Harrison, Christine J., Jiang, Yilin, Abrahamsson, Jonas, Arad-Cohen, Nira, Bart-Delabesse, Emmanuelle, Buldini, Barbara, De Moerloose, Barbara, Dworzak, Michael N., Elitzur, Sarah, Fernández Navarro, José M, Gerbing, Robert B., Goemans, Bianca F., de Groot-Kruseman, Hester A., Guest, Erin, Ha, Shau-Yin, Hasle, Henrik, Kelaidi, Charikleia, Lapillonne, Hélène, Leverger, Guy, Locatelli, Franco, Masetti, Riccardo, Miyamura, Takako, Norén-Nyström, Ulrika, Polychronopoulou, Sophia, Rasche, Mareike, Rubnitz, Jeffrey E., Stary, Jan, Tierens, Anne, Tomizawa, Daisuke, Zwaan, C Michel, Kaspers, Gertjan J L, van Weelderen, Romy E., Klein, Kim, Harrison, Christine J., Jiang, Yilin, Abrahamsson, Jonas, Arad-Cohen, Nira, Bart-Delabesse, Emmanuelle, Buldini, Barbara, De Moerloose, Barbara, Dworzak, Michael N., Elitzur, Sarah, Fernández Navarro, José M, Gerbing, Robert B., Goemans, Bianca F., de Groot-Kruseman, Hester A., Guest, Erin, Ha, Shau-Yin, Hasle, Henrik, Kelaidi, Charikleia, Lapillonne, Hélène, Leverger, Guy, Locatelli, Franco, Masetti, Riccardo, Miyamura, Takako, Norén-Nyström, Ulrika, Polychronopoulou, Sophia, Rasche, Mareike, Rubnitz, Jeffrey E., Stary, Jan, Tierens, Anne, Tomizawa, Daisuke, Zwaan, C Michel, and Kaspers, Gertjan J L

Abstract

Purpose: A previous study by the International Berlin-Frankfurt-Münster Study Group (I-BFM-SG) on childhood KMT2A-rearranged (KMT2A-r) AML demonstrated the prognostic value of the fusion partner. This I-BFM-SG study investigated the value of flow cytometry-based measurable residual disease (flow-MRD) and evaluated the benefit of allogeneic stem-cell transplantation (allo-SCT) in first complete remission (CR1) in this disease. Methods: A total of 1,130 children with KMT2A-r AML, diagnosed between January 2005 and December 2016, were assigned to high-risk (n = 402; 35.6%) or non-high-risk (n = 728; 64.4%) fusion partner-based groups. Flow-MRD levels at both end of induction 1 (EOI1) and 2 (EOI2) were available for 456 patients and were considered negative (<0.1%) or positive (≥0.1%). End points were 5-year event-free survival (EFS), cumulative incidence of relapse (CIR), and overall survival (OS). Results: The high-risk group had inferior EFS (30.3% high risk v 54.0% non-high risk; P < .0001), CIR (59.7% v 35.2%; P < .0001), and OS (49.2% v 70.5%; P < .0001). EOI2 MRD negativity was associated with superior EFS (n = 413; 47.6% MRD negativity v n = 43; 16.3% MRD positivity; P < .0001) and OS (n = 413; 66.0% v n = 43; 27.9%; P < .0001), and showed a trend toward lower CIR (n = 392; 46.1% v n = 26; 65.4%; P = .016). Similar results were obtained for patients with EOI2 MRD negativity within both risk groups, except that within the non-high-risk group, CIR was comparable with that of patients with EOI2 MRD positivity. Allo-SCT in CR1 only reduced CIR (hazard ratio, 0.5 [95% CI, 0.4 to 0.8]; P = .00096) within the high-risk group but did not improve OS. In multivariable analyses, EOI2 MRD positivity and high-risk group were independently associated with inferior EFS, CIR, and OS. Conclusion: EOI2 flow-MRD is an independent prognostic factor and should be included as risk stratification factor in childhood KMT2A-r AML. Treatment approaches other than allo-S

Published
2023
Full Text
View/download PDF

14. Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia:A Study by the International Berlin-Frankfurt-Munster Study Group

Author

van Weelderen, Romy E., Klein, Kim, Harrison, Christine J., Jiang, Yilin, Abrahamsson, Jonas, Arad-Cohen, Nira, Bart-Delabesse, Emmanuelle, Buldini, Barbara, De Moerloose, Barbara, Dworzak, Michael N., Elitzur, Sarah, Fernández Navarro, José M., Gerbing, Robert B., Goemans, Bianca F., de Groot-Kruseman, Hester A., Guest, Erin, Ha, Shau Yin, Hasle, Henrik, Kelaidi, Charikleia, Lapillonne, Hélène, Leverger, Guy, Locatelli, Franco, Masetti, Riccardo, Miyamura, Takako, Norén-Nyström, Ulrika, Polychronopoulou, Sophia, Rasche, Mareike, Rubnitz, Jeffrey E., Stary, Jan, Tierens, Anne, Tomizawa, Daisuke, Zwaan, C. Michel, Kaspers, Gertjan J.L., van Weelderen, Romy E., Klein, Kim, Harrison, Christine J., Jiang, Yilin, Abrahamsson, Jonas, Arad-Cohen, Nira, Bart-Delabesse, Emmanuelle, Buldini, Barbara, De Moerloose, Barbara, Dworzak, Michael N., Elitzur, Sarah, Fernández Navarro, José M., Gerbing, Robert B., Goemans, Bianca F., de Groot-Kruseman, Hester A., Guest, Erin, Ha, Shau Yin, Hasle, Henrik, Kelaidi, Charikleia, Lapillonne, Hélène, Leverger, Guy, Locatelli, Franco, Masetti, Riccardo, Miyamura, Takako, Norén-Nyström, Ulrika, Polychronopoulou, Sophia, Rasche, Mareike, Rubnitz, Jeffrey E., Stary, Jan, Tierens, Anne, Tomizawa, Daisuke, Zwaan, C. Michel, and Kaspers, Gertjan J.L.

Abstract

PURPOSE: A previous study by the International Berlin-Frankfurt-Münster Study Group (I-BFM-SG) on childhood KMT2A-rearranged (KMT2A-r) AML demonstrated the prognostic value of the fusion partner. This I-BFM-SG study investigated the value of flow cytometry-based measurable residual disease (flow-MRD) and evaluated the benefit of allogeneic stem-cell transplantation (allo-SCT) in first complete remission (CR1) in this disease. METHODS: A total of 1,130 children with KMT2A-r AML, diagnosed between January 2005 and December 2016, were assigned to high-risk (n = 402; 35.6%) or non-high-risk (n = 728; 64.4%) fusion partner-based groups. Flow-MRD levels at both end of induction 1 (EOI1) and 2 (EOI2) were available for 456 patients and were considered negative (<0.1%) or positive (≥0.1%). End points were 5-year event-free survival (EFS), cumulative incidence of relapse (CIR), and overall survival (OS). RESULTS: The high-risk group had inferior EFS (30.3% high risk v 54.0% non-high risk; P < .0001), CIR (59.7% v 35.2%; P < .0001), and OS (49.2% v 70.5%; P < .0001). EOI2 MRD negativity was associated with superior EFS (n = 413; 47.6% MRD negativity v n = 43; 16.3% MRD positivity; P < .0001) and OS (n = 413; 66.0% v n = 43; 27.9%; P < .0001), and showed a trend toward lower CIR (n = 392; 46.1% v n = 26; 65.4%; P = .016). Similar results were obtained for patients with EOI2 MRD negativity within both risk groups, except that within the non-high-risk group, CIR was comparable with that of patients with EOI2 MRD positivity. Allo-SCT in CR1 only reduced CIR (hazard ratio, 0.5 [95% CI, 0.4 to 0.8]; P = .00096) within the high-risk group but did not improve OS. In multivariable analyses, EOI2 MRD positivity and high-risk group were independently associated with inferior EFS, CIR, and OS. CONCLUSION: EOI2 flow-MRD is an independent prognostic factor and should be included as risk stratification factor in childhood KMT2A-r AML. Treatment approaches other than all

Published
2023

15. Azacitidine (Vidaza®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015)

Author

PMC Medisch specialisten, PMC Research, Apotheek O&O&O, Cancer, Speerpunt, Zorg en O&O, Child Health, Rubio-San-Simón, Alba, van Eijkelenburg, Natasha K.A., Hoogendijk, Raoull, Hasle, Henrik, Niemeyer, Charlotte M., Dworzak, Michael N., Zecca, Marco, Lopez-Yurda, Marta, Janssen, Julie M., Huitema, Alwin D.R., van den Heuvel-Eibrink, Marry M., Laille, Eric J., van Tinteren, Harm, Zwaan, Christian M., PMC Medisch specialisten, PMC Research, Apotheek O&O&O, Cancer, Speerpunt, Zorg en O&O, Child Health, Rubio-San-Simón, Alba, van Eijkelenburg, Natasha K.A., Hoogendijk, Raoull, Hasle, Henrik, Niemeyer, Charlotte M., Dworzak, Michael N., Zecca, Marco, Lopez-Yurda, Marta, Janssen, Julie M., Huitema, Alwin D.R., van den Heuvel-Eibrink, Marry M., Laille, Eric J., van Tinteren, Harm, and Zwaan, Christian M.

Published
2023

16. FCM marker importance for MRD assessment in T‐cell acute lymphoblastic leukemia: An AIEOP‐BFM‐ALL‐FLOW study group report.

Author

Kowarsch, Florian, Maurer‐Granofszky, Margarita, Weijler, Lisa, Wödlinger, Matthias, Reiter, Michael, Schumich, Angela, Feuerstein, Tamar, Sala, Simona, Nováková, Michaela, Faggin, Giovanni, Gaipa, Giuseppe, Hrusak, Ondrej, Buldini, Barbara, and Dworzak, Michael N.

Abstract

T‐lineage acute lymphoblastic leukemia (T‐ALL) accounts for about 15% of pediatric and about 25% of adult ALL cases. Minimal/measurable residual disease (MRD) assessed by flow cytometry (FCM) is an important prognostic indicator for risk stratification. In order to assess the MRD a limited number of antibodies directed against the most discriminative antigens must be selected. We propose a pipeline for evaluating the influence of different markers for cell population classification in FCM data. We use linear support vector machine, fitted to each sample individually to avoid issues with patient and laboratory variations. The best separating hyperplane direction as well as the influence of omitting specific markers is considered. Ninety‐one bone marrow samples of 43 pediatric T‐ALL patients from five reference laboratories were analyzed by FCM regarding marker importance for blast cell identification using combinations of eight different markers. For all laboratories, CD48 and CD99 were among the top three markers with strongest contribution to the optimal hyperplane, measured by median separating hyperplane coefficient size for all samples per center and time point (diagnosis, Day 15, Day 33). Based on the available limited set tested (CD3, CD4, CD5, CD7, CD8, CD45, CD48, CD99), our findings prove that CD48 and CD99 are useful markers for MRD monitoring in T‐ALL. The proposed pipeline can be applied for evaluation of other marker combinations in the future. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group

Author

van Weelderen, Romy E., primary, Klein, Kim, additional, Harrison, Christine J., additional, Jiang, Yilin, additional, Abrahamsson, Jonas, additional, Arad-Cohen, Nira, additional, Bart-Delabesse, Emmanuelle, additional, Buldini, Barbara, additional, De Moerloose, Barbara, additional, Dworzak, Michael N., additional, Elitzur, Sarah, additional, Fernández Navarro, José M., additional, Gerbing, Robert B., additional, Goemans, Bianca F., additional, de Groot-Kruseman, Hester A., additional, Guest, Erin, additional, Ha, Shau-Yin, additional, Hasle, Henrik, additional, Kelaidi, Charikleia, additional, Lapillonne, Hélène, additional, Leverger, Guy, additional, Locatelli, Franco, additional, Masetti, Riccardo, additional, Miyamura, Takako, additional, Norén-Nyström, Ulrika, additional, Polychronopoulou, Sophia, additional, Rasche, Mareike, additional, Rubnitz, Jeffrey E., additional, Stary, Jan, additional, Tierens, Anne, additional, Tomizawa, Daisuke, additional, Zwaan, C. Michel, additional, and Kaspers, Gertjan J.L., additional

Published
2023
Full Text
View/download PDF

19. Azacitidine (Vidaza®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015).

Author

Rubio-San-Simón, Alba, van Eijkelenburg, Natasha K. A., Hoogendijk, Raoull, Hasle, Henrik, Niemeyer, Charlotte M., Dworzak, Michael N., Zecca, Marco, Lopez-Yurda, Marta, Janssen, Julie M., Huitema, Alwin D. R., van den Heuvel-Eibrink, Marry M., Laille, Eric J., van Tinteren, Harm, and Zwaan, Christian M.

Subjects
AZACITIDINE, CHILD patients, HEMATOPOIETIC stem cell transplantation, CONSORTIA, MYELODYSPLASTIC syndromes
Abstract

Background: Advanced myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML) are rare hematological malignancies in children. A second allograft is recommended if a relapse occurs after hematopoietic stem cell transplantation, but the outcome is poor. Objective: We conducted a phase I/II multicenter study to evaluate the safety, pharmacokinetics, and activity of azacitidine in children with relapsed MDS/JMML prior to the second hematopoietic stem cell transplantation. Methods: Patients enrolled from June 2013 to March 2019 received azacitidine intravenously/subcutaneously once daily on days 1–7 of a 28-day cycle. The MDS and JMML cohorts followed a two-stage design separately, with a safety run-in for JMML. Response and safety data were used to evaluate efficacy and establish the recommended dose. Pharmacokinetics was also analyzed. The study closed prematurely because of low recruitment. Results: Six patients with MDS and four patients with JMML received a median of three and five cycles, respectively. Azacitidine 75 mg/m2 was well tolerated and plasma concentration–time profiles were similar to observed in adults. The most prevalent grade 3–4 adverse event was myelotoxicity. No responses were seen in patients with MDS, but 83% achieved stable disease; four patients underwent an allotransplant. Overall response rate in the JMML cohort was 75% (two complete responses; one partial response) and all responders underwent hematopoietic stem cell transplantation. One-year overall survival was 67% (95% confidence interval 38–100) in MDS and 50% (95% confidence interval 19–100) in JMML. Conclusions: Azacitidine 75 mg/m2 prior to a second hematopoietic stem cell transplantation is safe in children with relapsed MDS/JMML. Although the long-term advantage remains to be assessed, this study suggests that azacitidine is an efficacious option for relapsed JMML. Clinical Trial Registration: EudraCT 2010-022235-10. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

20. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004

Author

Creutzig, Ursula, Zimmermann, Martin, Bourquin, Jean-Pierre, Dworzak, Michael N., Fleischhack, Gudrun, Graf, Norbert, Klingebiel, Thomas, Kremens, Bernhard, Lehrnbecher, Thomas, von Neuhoff, Christine, Ritter, Jörg, Sander, Annette, Schrauder, André, Stackelberg, Arend von, Starý, Jan, and Reinhardt, Dirk

Published
2013
Full Text
View/download PDF

21. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel

Author

Creutzig, Ursula, van den Heuvel-Eibrink, Marry M., Gibson, Brenda, Dworzak, Michael N., Adachi, Souichi, de Bont, Eveline, Harbott, Jochen, Hasle, Henrik, Johnston, Donna, Kinoshita, Akitoshi, Lehrnbecher, Thomas, Leverger, Guy, Mejstrikova, Ester, Meshinchi, Soheil, Pession, Andrea, Raimondi, Susana C., Sung, Lillian, Stary, Jan, Zwaan, Christian M., Kaspers, Gertjan J.L., and Reinhardt, Dirk

Published
2012
Full Text
View/download PDF

23. Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study

Author

Coenen, Eva A., Raimondi, Susana C., Harbott, Jochen, Zimmermann, Martin, Alonzo, Todd A., Auvrignon, Anne, Beverloo, H. Berna, Chang, Myron, Creutzig, Ursula, Dworzak, Michael N., Forestier, Erik, Gibson, Brenda, Hasle, Henrik, Harrison, Christine J., Heerema, Nyla A., Kaspers, Gertjan J.L., Leszl, Anna, Litvinko, Nathalia, Lo Nigro, Luca, Morimoto, Akira, Perot, Christine, Reinhardt, Dirk, Rubnitz, Jeffrey E., Smith, Franklin O., Stary, Jan, Stasevich, Irina, Strehl, Sabine, Taga, Takashi, Tomizawa, Daisuke, Webb, David, Zemanova, Zuzana, Pieters, Rob, Zwaan, C. Michel, and van den Heuvel-Eibrink, Marry M.

Published
2011
Full Text
View/download PDF

29. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study

Author

Balgobind, Brian V., Raimondi, Susana C., Harbott, Jochen, Zimmermann, Martin, Alonzo, Todd A., Auvrignon, Anne, Beverloo, H. Berna, Chang, Myron, Creutzig, Ursula, Dworzak, Michael N., Forestier, Erik, Gibson, Brenda, Hasle, Henrik, Harrison, Christine J., Heerema, Nyla A., Kaspers, Gertjan J.L., Leszl, Anna, Litvinko, Nathalia, Nigro, Luca Lo, Morimoto, Akira, Perot, Christine, Pieters, Rob, Reinhardt, Dirk, Rubnitz, Jeffrey E., Smith, Franklin O., Stary, Jan, Stasevich, Irina, Strehl, Sabine, Taga, Takashi, Tomizawa, Daisuke, Webb, David, Zemanova, Zuzana, Zwaan, C. Michel, and van den Heuvel-Eibrink, Marry M.

Published
2009
Full Text
View/download PDF

33. The inferior prognosis of adolescents with acute lymphoblastic leukaemia (ALL) is caused by a higher rate of treatment-related mortality and not an increased relapse rate – a population-based analysis of 25 years of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group

Author

Pichler, Herbert, Reismüller, Bettina, Steiner, Manuel, Dworzak, Michael N., Pötschger, Ulrike, Urban, Christian, Meister, Bernhard, Schmitt, Klaus, Panzer-Grümayer, Renate, Haas, Oskar A., Attarbaschi, Andishe, and Mann, Georg

Published
2013
Full Text
View/download PDF

35. Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapy

Author

Pichler, Herbert, Möricke, Anja, Mann, Georg, Teigler-Schlegel, Andrea, Niggli, Felix, Nebral, Karin, König, Margit, Inthal, Andrea, Krehan, Daniela, Dworzak, Michael N., Janousek, Dasa, Harbott, Jochen, Schrappe, Martin, Gadner, Helmut, Strehl, Sabine, Haas, Oskar A., Panzer-Grümayer, Renate, and Attarbaschi, Andishe

Published
2010
Full Text
View/download PDF

39. AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia

Author

Dworzak, Michael N, Buldini, Barbara, Gaipa, Giuseppe, Ratei, Richard, Hrusak, Ondrej, Luria, Drorit, Rosenthal, Eti, Bourquin, Jean-Pierre, Sartor, Mary, Schumich, Angela, Karawajew, Leonid, Mejstrikova, Ester, Maglia, Oscar, Mann, Georg, Ludwig, Wolf-Dieter, Biondi, Andrea, Schrappe, Martin, Basso, Giuseppe, International-BFM-FLOW-network, et al, University of Zurich, and Dworzak, Michael N

Subjects
2734 Pathology and Forensic Medicine, 1307 Cell Biology, Histology, 10036 Medical Clinic, 610 Medicine & health, Cell Biology, 2722 Histology, Pathology and Forensic Medicine
Published
2018

44. Phospho-Profiling Linking Biology and Clinics in Pediatric Acute Myeloid Leukemia

Author

Schumich, Angela, primary, Prchal-Murphy, Michaela, additional, Maurer-Granofszky, Margarita, additional, Hoelbl-Kovacic, Andrea, additional, Mühlegger, Nora, additional, Pötschger, Ulrike, additional, Fajmann, Sabine, additional, Haas, Oskar A., additional, Nebral, Karin, additional, von Neuhoff, Nils, additional, Zimmermann, Martin, additional, Boztug, Heidrun, additional, Rasche, Mareike, additional, Dolezal, Marlies, additional, Walter, Christiane, additional, Reinhardt, Dirk, additional, Sexl, Veronika, additional, and Dworzak, Michael N., additional

Published
2019
Full Text
View/download PDF

47. CD371 cell surface expression: a unique feature of DUX4-rearranged acute lymphoblastic leukemia

Author

Schinnerl, Dagmar, Mejstrikova, Ester, Schumich, Angela, Zaliova, Marketa, Fortschegger, Klaus, Nebral, Karin, Attarbaschi, Andishe, Fiser, Karel, Kauer, Maximilian O, Popitsch, Niko, Haslinger, Sabrina, Inthal, Andrea, Buldini, Barbara, Basso, Giuseppe, Bourquin, Jean-Pierre, Gaipa, Giuseppe, Brüggemann, Monika, Feuerstein, Tamar, Maurer-Granofszky, Margarita, Panzer-Grümayer, Renate, Trka, Jan, Mann, Georg, Haas, Oskar A, Hrusak, Ondrej, Dworzak, Michael N, Strehl, Sabine, Schinnerl, Dagmar, Mejstrikova, Ester, Schumich, Angela, Zaliova, Marketa, Fortschegger, Klaus, Nebral, Karin, Attarbaschi, Andishe, Fiser, Karel, Kauer, Maximilian O, Popitsch, Niko, Haslinger, Sabrina, Inthal, Andrea, Buldini, Barbara, Basso, Giuseppe, Bourquin, Jean-Pierre, Gaipa, Giuseppe, Brüggemann, Monika, Feuerstein, Tamar, Maurer-Granofszky, Margarita, Panzer-Grümayer, Renate, Trka, Jan, Mann, Georg, Haas, Oskar A, Hrusak, Ondrej, Dworzak, Michael N, and Strehl, Sabine

Published
2019

48. CD371 cell surface expression: a unique feature of DUX4-rearranged acute lymphoblastic leukemia

Author

Schinnerl, Dagmar, primary, Mejstrikova, Ester, additional, Schumich, Angela, additional, Zaliova, Marketa, additional, Fortschegger, Klaus, additional, Nebral, Karin, additional, Attarbaschi, Andishe, additional, Fiser, Karel, additional, Kauer, Maximilian O., additional, Popitsch, Niko, additional, Haslinger, Sabrina, additional, Inthal, Andrea, additional, Buldini, Barbara, additional, Basso, Giuseppe, additional, Bourquin, Jean-Pierre, additional, Gaipa, Giuseppe, additional, Brüggemann, Monika, additional, Feuerstein, Tamar, additional, Maurer-Granofszky, Margarita, additional, Panzer-Grümayer, Renate, additional, Trka, Jan, additional, Mann, Georg, additional, Haas, Oskar A., additional, Hrusak, Ondrej, additional, Dworzak, Michael N., additional, and Strehl, Sabine, additional

Published
2019
Full Text
View/download PDF

49. Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study

Author

van Eijkelenburg, Natasha K.A., primary, Rasche, Mareike, additional, Ghazaly, Essam, additional, Dworzak, Michael N., additional, Klingebiel, Thomas, additional, Rossig, Claudia, additional, Leverger, Guy, additional, Stary, Jan, additional, De Bont, Eveline S.J.M., additional, Chitu, Dana A., additional, Bertrand, Yves, additional, Brethon, Benoit, additional, Strahm, Brigitte, additional, van der Sluis, Inge M., additional, Kaspers, Gertjan J.L., additional, Reinhardt, Dirk, additional, and Zwaan, C. Michel, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results